Marker Therapeutics Inc.

Company Overview

Business Model: Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing and commercializing novel T cell-based immunotherapies for hematological malignancies and solid tumor indications. The company's core technology, multi antigen recognizing ("MAR")-T cell therapy, is designed to selectively expand natural tumor-specific T cells from a patient's or donor's blood. This non-genetically engineered approach enables T cells to recognize hundreds of different epitopes within up to six tumor-specific antigens simultaneously, aiming to produce broad-spectrum anti-tumor activity and limit tumor immune escape. The infused MAR-T cells are intended to kill cancer cells expressing tumor-associated antigens (TAAs) and potentially recruit the patient's endogenous immune system. The underlying technology was licensed from Baylor College of Medicine in March 2018. Marker Therapeutics, Inc. is advancing two product candidates: an autologous MAR-T cell product (MT-601) for lymphoma and pancreatic cancer, and an Off-the-Shelf (OTS) product (MT-401-OTS) for various indications, including Acute Myeloid Leukemia and Myelodysplastic Syndromes. The company believes its non-genetically engineered approach offers advantages over CAR-T therapies, including enhanced tumoricidal effect, minimized tumor immune escape, a favorable safety profile (no immune effector cell-associated neurotoxicity syndrome (ICANS) or other severe adverse effects (SAEs) attributed to MAR-T cell therapies to date), reduced manufacturing complexity, and lower cost.

Market Position: Marker Therapeutics, Inc. operates in the highly competitive and rapidly evolving biotechnology and biopharmaceutical industries. The company is a clinical-stage entity with no approved products, focusing on areas of high unmet medical need, such as relapsed/refractory lymphoma patients who have failed or are ineligible for anti-CD19 CAR-T cell therapy. MT-601 is positioned as the only natural T cell product targeting multiple tumor antigens for CAR relapse lymphoma patients. The competitive landscape includes numerous pharmaceutical and biotechnology companies, academic institutions, and research organizations, many of which possess significantly greater financial, technical, and human resources. Existing approved CD19-directed CAR-T cell therapies (Yescarta, Kymriah, Tecartus, and Bryanzi) for relapsed lymphoma face high relapse rates (40-60%), indicating a need for alternative treatments. Other competitors are developing non-CD19 targeting CAR-T cells, multi-targeted CAR-T cells, NK-CAR therapies, and bispecific antibodies. Marker Therapeutics, Inc. believes its non-engineered T cell therapy approaches may be synergistic with and improve upon therapies developed by potential competitors.

Recent Strategic Developments:

• MT-601 for Lymphoma: The FDA cleared the Investigational New Drug (IND) application for MT-601 in August 2022. The Phase 1 APOLLO study was initiated in January 2023, with first enrollment in June 2023. As of a December 2024 update (data cutoff September 10, 2024), clinical data for 9 patients showed an early objective response rate of 78%, with 44.4% achieving complete response at first assessment. MT-601 was well tolerated, with no ICANS and one reported Grade 1 cytokine release syndrome (CRS). Immunomonitoring data indicated that lymphodepletion enhanced MAR-T cell expansion and persistence in vivo.
• MT-601 for Pancreatic Cancer: Interim data from a Baylor College of Medicine-conducted Phase 1/2 TACTOPS trial showed objective responses in 4 of 13 (31%) patients with unresectable or metastatic pancreatic cancer, with no observed CRS or neurotoxicity. The FDA granted orphan drug designation for MT-601 in pancreatic cancer in January 2022. An IND for the Phase 1 PANACEA study (MT-601 in combination with front-line chemotherapy) was cleared in November 2022. The company secured a $9.5 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT) and a $2 million grant from the NIH Small Business Innovation Research (SBIR) program to support MT-601's clinical investigation in pancreatic cancer.
• MT-401 for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS): In January 2024, Marker Therapeutics, Inc. discontinued the Phase 2 ARTEMIS study to prioritize the MT-401-OTS program. MT-401 had previously received orphan drug designation from the FDA (April 2020) and the European Medicines Agency (2023) for AML. Prior BCM Phase 1 trials showed MT-401 was well tolerated with promising relapse-free survival and overall survival rates in post-allogeneic hematopoietic stem cell transplant AML/MDS patients. Marker Therapeutics, Inc.'s improved manufacturing process for MT-401 reduced production time to 9 days (from >30 days), decreased interventions by 90%, and increased antigen specificity, diversity, and in vitro potency by four-fold.
• Off-the-Shelf (OTS) MT-401 Program: The company is focusing on MT-401-OTS for AML and MDS, aiming for treatment delivery in as little as 72 hours. The U.S. FDA has cleared the clinical protocol, and a cellular inventory from healthy donors is being expanded. A single donor is estimated to provide treatment for approximately 40 patients, and products are stable for over a year in liquid nitrogen. The first patient dosing is expected in the second half of 2025. Grant funding from the FDA Orphan Products Grant, NIH SBIR, and CPRIT has been shifted to support this program.
• Manufacturing Strategy: Marker Therapeutics, Inc. transitioned from operating its own cGMP manufacturing facility (opened July 2021) by assigning leases, selling equipment, and related contracts to Cell Ready LLC on June 26, 2023. The company now relies on third parties, primarily Baylor College of Medicine, for clinical manufacturing. A Master Services Agreement with Cell Ready LLC, entered in February 2024, was mutually terminated on March 27, 2025, with a settlement payment of approximately $453,000. Marker Therapeutics, Inc. is evaluating additional third-party manufacturing partners for future pivotal trials and commercial production.
• Grant Funding: The company has received significant grant funding, including $13.1 million from CPRIT (August 2021) for MT-401, $2.0 million from the FDA Orphan Products Grant (September 2022) for MT-401, $2.0 million from NIH SBIR (May 2023) for MT-401, $2.0 million from NIH - National Cancer Institute (June 2024) for pancreatic cancer, $2.0 million from SBIR (August 2024) for MT-601 in non-Hodgkin's lymphoma, $2.0 million from NIH SBIR (August 2024) for MT-601 in pancreatic cancer, and an additional $9.5 million from CPRIT (December 2024) for MT-601 in metastatic pancreatic cancer.

Geographic Footprint: Marker Therapeutics, Inc.'s principal executive offices are located in Houston, Texas. Clinical trials are conducted across the United States. The company holds a European patent (EP 2470644) licensed from Baylor College of Medicine, and MT-401 has received orphan drug designation from the European Medicines Agency, indicating an international focus for intellectual property protection and potential future market access.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: Not applicable (no Cost of Goods Sold reported).
• Operating Margin: -168.7% (2024), -440.4% (2023)
• Net Margin: -162.8% (2024), -248.8% (2023)

Investment in Growth:

• R&D Expenditure: $13.5 million (204.3% of revenue) in 2024, $10.4 million (314.1% of revenue) in 2023.
• Capital Expenditures: Not explicitly stated as a separate line item.
• Strategic Investments (Funding for R&D initiatives):
  • $9.5 million grant from Cancer Prevention & Research Institute of Texas (CPRIT) for MT-601 in metastatic pancreatic cancer (awarded December 2024).
  • $2.0 million grant from NIH Small Business Innovation Research (SBIR) program for MT-601 in non-Hodgkin's lymphoma (awarded August 2024).
  • $2.0 million grant from NIH SBIR program for MT-601 in pancreatic cancer (awarded August 2024).
  • $2.0 million grant from National Institutes of Health - National Cancer Institute for pancreatic cancer (awarded June 2024).
  • $2.0 million grant from NIH SBIR program for MT-401 (awarded May 2023).
  • $2.0 million grant from FDA Orphan Products Grant program for MT-401 (awarded September 2022).
  • $13.1 million grant from CPRIT for MT-401 clinical investigation (awarded August 2021).

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: No equity securities were repurchased during the reported periods.
• Dividend Payments: No cash dividends have been declared or paid on common stock, and the company does not anticipate paying cash dividends in the foreseeable future due to recurring losses.
• Dividend Yield: Not applicable.
• Future Capital Return Commitments: None disclosed.

Balance Sheet Position:

• Cash and Equivalents: $19.2 million (2024), $15.1 million (2023)
• Total Liabilities: $3.5 million (2024), $3.1 million (2023)
• Net Cash Position: $15.7 million (2024), $12.0 million (2023)
• Credit Rating: Not disclosed.
• Debt Maturity Profile: Not disclosed.

Cash Flow Generation:

• Operating Cash Flow: $(10.9) million (2024), $(10.3) million (2023)
• Free Cash Flow: Not explicitly stated or calculable from provided data.
• Cash Conversion Metrics: Not disclosed.

Operational Excellence

Production & Service Model: Marker Therapeutics, Inc.'s operational philosophy centers on developing non-genetically engineered T cell-based immunotherapies. The MAR-T cell technology involves selectively expanding natural tumor-specific T cells from a patient's or donor's blood. The manufacturing process includes in vitro co-culturing of antigen-presenting cells with peripheral blood mononuclear cells (PBMCs) and stimulating them with libraries of overlapping peptides derived from target antigens. This process is designed to induce both CD4+ (helper) and CD8+ (cytotoxic) T cells. The resulting product is a mix of these T cells, typically comprising approximately 4,000 unique T cell clonotypes per patient dose, capable of recognizing up to six different tumor-associated antigens. The manufacturing process has been optimized, reducing production time from 36 days to 9 days, decreasing interventions by 90%, and increasing antigen specificity, diversity, and in vitro potency by four-fold. The final product undergoes testing for identity, sterility, phenotype, and functionality before being frozen and transported for patient infusion, with a standard lymphoma dose ranging from 100 to 400 million cells per adult patient.

Supply Chain Architecture: Marker Therapeutics, Inc. relies entirely on third parties for the clinical and, once approved, commercial manufacture of its product candidates. The company previously operated its own cGMP manufacturing facility but divested these assets to Cell Ready LLC in June 2023. Currently, Baylor College of Medicine serves as a contract manufacturer for clinical development. A Master Services Agreement with Cell Ready LLC for product supply, established in February 2024, was mutually terminated in March 2025. The company is actively evaluating and qualifying additional third-party manufacturing partners to ensure multiple sources of clinical and commercial supply, particularly in anticipation of a larger pivotal trial for lymphoma in 2026. The supply chain is dependent on a limited number of vendors for specialized equipment and materials, which poses a risk if these suppliers cannot meet demand or cease operations.

Key Suppliers & Partners:

• Manufacturing & Research: Baylor College of Medicine - Provides licensed technology, conducts research, early-stage and Phase 2 clinical trials, offers access to clinical data, and supplies product manufacturing and support.
• Equipment & Reagents: Wilson Wolf, Almac - Suppliers of critical materials and equipment for the manufacturing process.
• Manufacturing: Cell Ready LLC - Previously a contract development and manufacturing organization (CDMO) for product supply and services; the agreement was terminated in March 2025.

Facility Network:

• Principal Business Office: Utilizes office space provided by Baylor College of Medicine at 2450 Holcombe Blvd, Suite BCM-A, MS: BCM251, Houston, TX 77021.
• Manufacturing: Does not own or operate cGMP manufacturing facilities; relies on third-party facilities, including those of Baylor College of Medicine.

Operational Metrics:

• Manufacturing time: Reduced from 36 days to 9 days.
• Interventions during production: 90% decrease.
• Antigen specificity and diversity: Increased.
• Potency: 4x increase in vitro.
• Off-the-Shelf (OTS) product capacity: A single donor could provide treatment for approximately 40 patients.
• OTS product stability: More than a year in liquid nitrogen.

Market Access & Customer Relationships

Go-to-Market Strategy: Marker Therapeutics, Inc. plans to initially seek regulatory approval for its product candidates in patients with relapsed or refractory metastatic disease. If successful, the company intends to pursue approvals for earlier lines of treatment and potentially as a first-line therapy. The strategy for commercialization involves substantial reliance on strategic collaborations for marketing and distribution, as the company currently lacks an internal sales, marketing, and distribution organization. Building these capabilities internally or through third-party arrangements will be critical for generating product revenue and achieving profitability.

Customer Portfolio: The company's product candidates target specific patient populations with high unmet medical needs:

• Lymphoma: Patients with relapsed or refractory lymphoma who have failed or are ineligible for anti-CD19 CAR-T cell therapy.
• Pancreatic Cancer: Patients with unresectable or metastatic pancreatic adenocarcinoma, including those in combination with front-line chemotherapy.
• Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS): Patients, particularly those post-allogeneic hematopoietic stem cell transplant, with measurable residual disease or active disease.

Geographic Revenue Distribution: Not applicable, as the company does not currently generate revenue from product sales. All reported revenue is from grants, primarily from U.S.-based government agencies and non-profit foundations.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The biotechnology and biopharmaceutical industries are characterized by rapid technological advancements and intense competition. Success is heavily influenced by scientific and technological factors, including patent protection, commercialization capabilities, and regulatory approvals. There is a significant unmet medical need in cancer treatment, particularly for patients with relapsed lymphoma after CAR-T therapy. T cell therapy is recognized as a promising branch of immunotherapy, but CAR-T therapies are associated with severe side effects and potential risks of secondary malignancies. The market for new oncology therapies typically begins with approvals for relapsed or refractory metastatic disease.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• CD19-directed CAR-T cell therapies: Yescarta, Kymriah, Tecartus, and Bryanzi, which are approved for relapsed lymphoma but face high relapse rates.
• Other immunotherapies: Companies developing non-CD19 targeting CAR-T cells, multi-targeted CAR-T cells, NK-CAR therapies, and bispecific antibodies for cancer treatment.
• Biopharmaceutical firms: Specialized companies in the United States, Europe, and other regions.
• Large pharmaceutical companies: Many have internal biotechnology capabilities or collaborations, possessing greater financial, marketing, and human resources.
• Academic and research institutions: Compete in scientific personnel recruitment and proprietary technology development.

Emerging Competitive Threats: The company faces threats from new market entrants, disruptive technologies, and alternative therapeutic solutions. Competitors may achieve patent protection, regulatory approvals, or commercialization of products that are more effective or cost-efficient. Existing therapies with established safety and efficacy profiles, as well as new small molecules and other therapeutic agents, also pose competitive challenges.

Competitive Response Strategy: Marker Therapeutics, Inc.'s strategy includes expediting the clinical development, regulatory approval, and commercialization of its lead product candidates, prioritizing MT-601 in lymphoma and MT-401-OTS in AML/MDS. The company aims to enhance its competitive advantage by continuing collaborations with partners like Baylor College of Medicine to optimize manufacturing processes, product quality, and commercial scalability. Furthermore, it plans to invest in its platform to expand indications by customizing targeted antigens and exploring different dosing regimens, leveraging the expertise of its scientific founders and advisors.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics: The company faces significant risks due to its clinical-stage status, with all product candidates requiring extensive preclinical and clinical development, regulatory approval, and commercialization efforts. The lengthy and unpredictable FDA regulatory process, coupled with limited FDA experience with novel cell therapies, could lead to substantial delays or prevent approval. Early clinical trial results may not be predictive of later-stage outcomes, and unexpected serious adverse effects could halt development. The highly competitive biotechnology industry, characterized by rapid technological advancements, poses a risk of product obsolescence and competition from better-resourced entities. Even if approved, market acceptance among physicians, patients, and payors is uncertain, and the initial target patient populations may be small, limiting commercial potential. New regulatory pathways for biosimilars could reduce market exclusivity. The company also faces inherent product liability risks from clinical testing and potential commercialization, which could result in substantial liabilities.

Technology Disruption: The rapid pace of innovation in the biotechnology and immunotherapy sectors means that current or proposed immunotherapies could become obsolete before the company recoups its research and development expenses. Competitors may develop more effective, safer, or lower-cost alternative treatments.

Operational & Execution Risks

Supply Chain Vulnerabilities: Marker Therapeutics, Inc. relies entirely on third-party vendors and contract manufacturing organizations (CMOs) for manufacturing and cell processing. This reliance exposes the company to risks such as limited manufacturing capacity, failure to meet stringent regulatory requirements (cGMP), disruptions, delays, or cessation of operations by these third parties. The company's dependence on a limited number of sole-source or limited-source vendors for specialized equipment and materials could impair the manufacture and supply of its product candidates. The complex manufacturing process for biologics, particularly personalized cell therapies, is susceptible to product loss or failure due to logistical issues, cell variability, contamination, equipment failure, or human error. The new 9-day manufacturing process, while improved, is still subject to uncertainties regarding commercial viability, cost reduction, and scalability.

Capacity Constraints: Third-party manufacturers may not be able to meet the company's needs regarding timing, quantity, or quality of product supply. Any required increase in production capacity could necessitate significant investments or subcontracting, potentially leading to delays and increased costs.

Financial & Regulatory Risks

Market & Financial Risks: Marker Therapeutics, Inc. has a history of operating losses and expects these losses to continue indefinitely, raising substantial doubt about its ability to continue as a going concern. Future operations are highly dependent on securing additional financing through equity offerings, debt, or grants, which may not be available on favorable terms or at all, especially given current global economic conditions, inflation, and capital market volatility. Future equity issuances or warrant/option exercises could significantly dilute existing shareholders. The company does not intend to pay cash dividends. Its ability to utilize net operating loss (NOL) carryforwards to offset future taxable income may be limited by Section 382 ownership changes or state tax laws.

Regulatory & Compliance Risks: The company is subject to extensive and rigorous regulation by the FDA and international authorities. The approval process is costly, time-consuming, and uncertain, particularly for novel cell therapies where regulatory experience is limited. Post-approval, the company will face ongoing regulatory obligations, including surveillance, risk evaluation and mitigation strategies (REMS), and cGMP compliance, with potential penalties for non-compliance. Obtaining approval in one jurisdiction does not guarantee approval in others, and international markets may have different requirements, including price controls and reimbursement approvals. The company's business activities are subject to complex federal and state healthcare laws (e.g., Anti-Kickback Statute, False Claims Act, HIPAA, Physician Payments Sunshine Act), and non-compliance could lead to significant penalties, reputational harm, and operational restructuring. Recent and future healthcare reform measures (e.g., ACA, IRA) could adversely affect product pricing, coverage, and reimbursement.

Data Privacy & Security: The company's processing of personal and sensitive data (including clinical trial subject data) subjects it to stringent and evolving data privacy and security laws (e.g., HIPAA, CCPA, EU GDPR, UK GDPR, LGPD, PIPL). Actual or perceived failures to comply, or security incidents (cyberattacks, ransomware), could lead to regulatory investigations, litigation, fines, business disruptions, and reputational damage. Reliance on third-party IT service providers adds to this risk.

Geopolitical & External Risks

Geopolitical Exposure: Unfavorable global political or economic conditions, including military conflicts, trade relations, and sanctions, could adversely affect the company's business, supply chain, and the operations of its third-party partners.

Innovation & Technology Leadership

Research & Development Focus: Marker Therapeutics, Inc.'s R&D efforts are centered on its multi antigen recognizing ("MAR")-T cell technology, which involves the selective expansion of non-genetically engineered, tumor-specific T cells. The core technology areas include targeting multiple tumor-associated antigens (TAAs) to achieve broad-spectrum anti-tumor activity and minimize immune escape. Current product candidates, MT-601 (autologous) and MT-401-OTS (Off-the-Shelf), target specific TAAs such as Survivin, PRAME, WT1, NY-ESO-1, SSX-2, and MAGEA-4. The company is also exploring the potential of combining MAR-T cell products with other therapies and investigating new product opportunities by customizing targeted antigens to expand indications into solid tumors and other hematologic malignancies, as well as optimizing dosing strategies.

Innovation Pipeline:

• MT-601 for Lymphoma: Currently in a Phase 1 APOLLO study for relapsed/refractory lymphoma patients who have failed or are ineligible for anti-CD19 CAR-T cell therapy.
• MT-601 for Pancreatic Cancer: In an ongoing Phase 1/2 TACTOPS clinical trial (conducted by Baylor College of Medicine) and a company-sponsored Phase 1 PANACEA study in combination with front-line chemotherapy.
• MT-401-OTS for AML and MDS: Clinical protocol cleared, with the first patient dosing expected in the second half of 2025. The company is establishing a pre-manufactured cellular inventory from healthy donors.

Intellectual Property Portfolio:

• Patent Strategy: The company's intellectual property strategy focuses on licensing key patents and patent applications to enhance its technology position. It holds a worldwide, exclusive license from Baylor College of Medicine for rights to certain intellectual property, including European patent EP 2470644 (estimated expiration August 24, 2030). The portfolio includes patent applications covering methods of generating multi-antigen specific T cell products and their therapeutic uses. The company periodically reassesses the value of its patents.
• Licensing Programs: The exclusive license agreement with Baylor College of Medicine (March 2018) includes royalty payments on net sales (ranging from 0.65% to 5.0%, increasing with aggregate net sales), milestone payments (up to $64.85 million) tied to clinical development, FDA approval, and net sales goals, sublicensing fees, and reimbursement for patent-related expenses. A liquidity incentive payment of 0.5% of liquidity event proceeds is also due to Baylor College of Medicine.
• IP Litigation: The company acknowledges the prevalence of patent and intellectual property litigation in the biotechnology and pharmaceutical industries and the potential for costly and time-consuming disputes regarding infringement, validity, or enforceability of patents.

Technology Partnerships:

• Strategic Alliances: Baylor College of Medicine is a key strategic partner, serving as a founding institution and providing scientific founders, research collaborations, early-stage clinical trial conduct, and manufacturing support.
• Research Collaborations: The company has Sponsored Research Agreements with Baylor College of Medicine's Center for Cell and Gene Therapy for research activities.
• Manufacturing Collaborations: While a Master Services Agreement with Cell Ready LLC was terminated, the company continues to work with Baylor College of Medicine for manufacturing and is actively evaluating and qualifying additional third-party manufacturing partners.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The company is highly dependent on its key management, scientific, and medical personnel, particularly Juan Vera, M.D. The loss of such personnel could lead to delays in product development. The company has a priority to train additional qualified scientific and medical personnel to ensure business continuity.

Board Composition: The board of directors includes N. David Eansor (Chairman), Katharine Knobil, and Steve Elms, in addition to Juan Vera, M.D. The board addresses cybersecurity risk management as part of its general oversight function.

Human Capital Strategy

Workforce Composition: As of December 31, 2024, Marker Therapeutics, Inc. had 5 full-time employees, comprising 1 clinical employee and 4 in administrative support roles.

Talent Management: Acquisition & Retention: The company's talent management objectives include identifying, recruiting, retaining, incentivizing, and integrating employees. Equity incentive plans are utilized to attract, retain, and motivate selected employees, consultants, and directors through equity-based compensation awards. Diversity & Development: Marker Therapeutics, Inc. strives to create a diverse environment, with 100% of its executive officers identifying as women or members of an underrepresented minority group.

Consultants: The company engages a network of leading academic scientists, clinicians, and regulatory experts as consultants. These individuals provide expertise in cellular biology, molecular biology, oncology, clinical development, manufacturing, and regulatory affairs, serving as important contacts within the broader scientific and clinical communities. Consultants are retained through agreements that include consulting fees, expense reimbursement, and stock options with vesting requirements.

Regulatory Environment & Compliance

Regulatory Framework: Marker Therapeutics, Inc.'s product candidates and operations are subject to extensive and rigorous regulation by the FDA in the United States and comparable authorities in foreign countries. The regulatory process for biologics, including preclinical testing (GLP), IND submissions, clinical trials (GCP, Phases 1-3), Biologics License Application (BLA) submission and review, and manufacturing facility inspections (cGMP), is lengthy, complex, and expensive. The novel nature of the company's product candidates, particularly as adoptive T cell therapies, may lead to a more uncertain and prolonged regulatory approval pathway due to limited prior experience of regulatory agencies with such technologies. The company has received Orphan Drug Designation from the FDA for MT-401 (AML) and MT-601 (pancreatic cancer), and from the European Medicines Agency (EMA) for MT-401, which may provide 7 years of market exclusivity upon first approval, subject to certain conditions. Post-approval, products are subject to ongoing surveillance, reporting requirements, and potential Risk Evaluation and Mitigation Strategies (REMS). Compliance with regulatory requirements in international markets is also critical, with varying approval procedures, reimbursement policies, and potential price controls. The European unitary patent system, introduced in late 2023, adds complexity and uncertainty to patent enforcement in Europe.

Legal Proceedings: The company is not currently a party to any material legal proceedings that are expected to have an adverse effect on its business, operating results, or financial condition. However, it may become involved in legal proceedings in the ordinary course of business, including claims from employees, consultants, vendors, or intellectual property infringement disputes.

Tax Strategy & Considerations

Tax Profile: Marker Therapeutics, Inc. recognized $50,000 in state tax expense in 2024 and $4,000 in 2023. The company's tax planning is influenced by recent tax reforms, including the Inflation Reduction Act of 2022, which impacts Medicare drug pricing and imposes rebates, and the Tax Cuts and Jobs Act of 2017. Effective for tax years beginning after December 31, 2021, IRC Section 174 requires the capitalization and amortization of research and experimentation (R&E) expenses over 5 years for U.S. activities and 15 years for ex-U.S. activities. The company anticipates remaining in a loss position even after this change and does not expect to pay cash taxes in the near future due to R&E capitalization and amortization.

Tax Loss and Credit Carryforwards: As of December 31, 2024, the company had approximately $138.3 million in federal net operating loss (NOL) carryforwards, with $38.4 million expiring between 2030 and 2037, and $99.9 million (generated 2018 and thereafter) carrying forward indefinitely but subject to an 80% taxable income limitation. State NOL carryforwards totaled $38.8 million, with $21.9 million beginning to expire in 2035, and $16.9 million (generated 2018 and thereafter) carrying forward indefinitely, subject to an 80% taxable income limitation. The company also has research and development tax credit carryforwards that begin to expire in 2030. A 100% valuation allowance of $41.0 million (2024) and $39.7 million (2023) has been recorded against deferred tax assets due to the history of losses and uncertainty regarding their realization. The usage of NOLs may be subject to limitations under Section 382 of the Internal Revenue Code due to potential ownership changes.

Insurance & Risk Transfer

Risk Management Framework: Marker Therapeutics, Inc. employs a risk management framework that includes insurance coverage and other risk transfer mechanisms.

• Insurance Coverage: The company maintains products and clinical trial liability insurance policies to mitigate risks associated with the clinical testing and potential commercialization of its product candidates. It also carries cybersecurity insurance to cover expenses related to breach events, including notification, credit monitoring, investigation, crisis management, public relations, and legal advice. Additionally, property and casualty insurance is maintained, which may cover data restoration, physical damage, or third-party injuries resulting from cybersecurity incidents.
• Risk Transfer Mechanisms: Not explicitly detailed beyond the mentioned insurance coverages.